Related Experiment Videos
Coronary artery disease: the Scandinavian Simvastatin Survival Study experience
1Department of Cardiology, Aker Hospital, Oslo, Norway.
Abstract:
Although hyperlipidemia is a known risk factor for coronary artery disease, lipid-lowering agents were not used widely until recently because evidence was lacking that they could prolong life. In 1987, a large clinical trial, the Scandinavian Simvastatin Survival Study (4S), was designed to test whether such therapy could decrease all-cause mortality in patients with documented coronary artery disease. The prospective, randomized, multicenter trial included 4,444 patients who had had angina pectoris or myocardial infarction (MI), serum total cholesterol of 213-310 mg/dL, and serum triglycerides < or =221 mg/dL. Patients received either simvastatin 20-40 mg/day or placebo and were followed for a median of 5.4 years. Therapy decreased total cholesterol an average of 25%; low-density lipoprotein (LDL) cholesterol, 35%; and triglyceride levels, 10%. Therapy increased high-density lipoprotein (HDL) cholesterol levels 8%. Although noncardiac death rates were similar among the groups, the relative risk of mortality (from any cause) was decreased 30%, and the relative risk of coronary mortality was decreased 42% in the simvastatin arm. The mortality risk reductions were profound in patients > or =60 years of age. Treatment also significantly decreased the relative risk of coronary events and the need for bypass surgery or coronary angioplasty. Patients with diabetes also benefited significantly from simvastatin therapy. The reductions in relative risk of major coronary events were achieved irrespective of such baseline risk factors as hypertension and smoking and such medication factors as aspirin, beta-blocker, and calcium-antagonist use. Simvastatin therapy has been shown to be cost-effective, decreasing per-patient hospitalization costs by 31% or $3,872 in 1995 dollars.
Insights
The Scandinavian Simvastatin Survival Study (4S) demonstrated that simvastatin significantly reduces mortality in patients with coronary artery disease. This lipid-lowering therapy proved effective in lowering cholesterol and preventing cardiovascular events.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Hyperlipidemia is a significant risk factor for coronary artery disease (CAD).
- Limited evidence previously existed on the life-prolonging effects of lipid-lowering agents.
- The Scandinavian Simvastatin Survival Study (4S) was initiated to address this knowledge gap.
Purpose of the Study:
- To evaluate the efficacy of simvastatin in reducing all-cause mortality in patients with established coronary artery disease.
- To assess the impact of simvastatin on lipid profiles and cardiovascular events.
Main Methods:
- A prospective, randomized, multicenter trial involving 4,444 patients with angina pectoris or myocardial infarction.
- Participants had specific ranges for total cholesterol and triglycerides.
- Patients were randomized to receive either simvastatin (20-40 mg/day) or a placebo for a median follow-up of 5.4 years.
Main Results:
- Simvastatin reduced total cholesterol by 25%, LDL cholesterol by 35%, and triglycerides by 10%.
- HDL cholesterol increased by 8% with simvastatin therapy.
- A 30% reduction in all-cause mortality and a 42% reduction in coronary mortality were observed in the simvastatin group.
- Significant benefits were noted in patients aged 60 and older, those with diabetes, and in reducing coronary events and the need for revascularization procedures.
- Cost-effectiveness was demonstrated through a 31% decrease in hospitalization costs.
Conclusions:
- Simvastatin therapy significantly reduces mortality and cardiovascular events in patients with coronary artery disease.
- The benefits of simvastatin are evident across various patient subgroups, including the elderly and those with diabetes.
- Simvastatin is a cost-effective treatment option for managing hyperlipidemia and improving outcomes in patients with established CAD.